Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YK012 in B-cell Acute Lymphoblastic Leukemia
NCT06580301Phase 2Recruiting
- Sponsor
- Excyte Biopharma Ltd
- Start
- Sep 2024
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of YK012 in acute lymphoblastic leukemia (ALL), sponsored by Excyte Biopharma Ltd. Started Sep 2024; status: recruiting.
02
Drugs
YK012
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT06580301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06580301.